Precision Cancer Therapy in Rare Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

March 20, 2025

Primary Completion Date

November 30, 2033

Study Completion Date

August 1, 2036

Conditions
Rare Malignant Neoplasm
Interventions
DRUG

Imatinib

imatinib treatment based on molecular alterations

DRUG

Trametinib

According to biomarkers

DRUG

Dabrafenib

According to biomarkers

Trial Locations (1)

0310

RECRUITING

Oslo University Hospital, Oslo

All Listed Sponsors
collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

University Hospital of North Norway

OTHER

collaborator

StOlavs Hospital

UNKNOWN

collaborator

Nordlandssykehuset HF

OTHER

collaborator

Helse Nord-Trøndelag HF

OTHER

collaborator

Sorlandet Hospital HF

OTHER_GOV

collaborator

Møre og Romsdal Hospital Trust

OTHER

collaborator

The Hospital of Vestfold

OTHER

collaborator

Helse Fonna

OTHER

collaborator

Haukeland University Hospital

OTHER

collaborator

Sykehuset Ostfold

OTHER

collaborator

Helse Forde

OTHER

collaborator

Sykehuset Innlandet HF

OTHER

lead

Oslo University Hospital

OTHER